CurrentCignaPolicy IP0319

Rituximab products for non-oncology indications

Cigna coverage policy that defines medical necessity, dosing, reauthorization, and coding for rituximab intravenous products (Rituxan, Riabni, Ruxience, Truxima) when used for non-oncology indications across applicable commercial plans.

Policy Summary

PayerCigna

PolicyRituximab products for non-oncology indications

Policy CodePolicy IP0319

Change TypeDocumentation and preferencing updates

Effective DateAug 15, 2025

Next Review Date

Key ActionWhen requesting coverage for NMOSD, submit documentation showing a positive anti-aquaporin-4 (AQP4) serum test and follow product-specific non-preferred criteria when Rituxan is prescribed.

SourceLink

POLICY UPDATE CHANGES

Preferencing Product Table changed: removed requirement 'Individual has previously started on or is currently receiving Rituxan (rituximab).'

Added documentation instructions for Neuromyelitis Optica Spectrum Disorder (NMOSD): diagnosis must be confirmed by a positive blood serum test for anti-aquaporin-4 antibody [documentation required].

Updated NMOSD criterion from 'Documented diagnosis of neuromyelitis optica spectrum disorder' to 'diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 antibody [documentation required]'.

16+Non-oncology indications with explicit criteria listed

up to 12 monthsInitial and reauthorization approval duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Listed HCPCS codes for covered rituximab products

3Referenced major guideline sources (examples shown in this part)

2Material policy edits recorded in Revision Details

Medical Necessity Criteria for Rituximab (non-oncology)

General medical necessity statement

Rituximab products (Rituxan, Riabni, Ruxience, Truxima) are considered medically necessary when ONE of the following non-oncology indications and their specific criteria are met:

Conditions considered experimental, investigational or unproven (Not covered)

Rituximab products are considered experimental, investigational, or unproven for any other non-oncology use not listed above, including but not limited to:

ANY of the following

Pediatric Acute-Onset Neuropsychiatric Syndrome/Pediatric Autoimmune Neuropsychiatric Disorders (PANS/PANDAS)
Concomitant use with Enspryng (satralizumab), Soliris (eculizumab), Ultomiris (ravulizumab), or Uplizna (inebilizumab)
Rituxan Hycela (rituximab and hyaluronidase human) for any non-oncology indication

Documentation requirement for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Coverage for NMOSD-related therapies requires confirmation of diagnosis by the following:

ALL of the following

Diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 (AQP4) antibody
Documentation required in the prior authorization submission

Preferencing Product Table - Rituximab condition removed

Policy-level product preferencing for rituximab was modified as follows:

ALL of the following

The previous criterion 'Individual has previously started on or is currently receiving Rituxan (rituximab)' was removed from the preferencing table
No longer required for preferencing decisions per revision dated 7/1/2025

Relevant Billing Codes

Covered HCPCS codes for rituximab productsHCPCSCovered

J9312	Injection, rituximab, 10 mg
Q5115	Injection, rituximab-abbs (Truxima), 10 mg
Q5119	Injection, rituximab-pvvr (Ruxience), 10 mg
Q5123	Injection, rituximab-arrx (Riabni), 10 mg

Prior Authorization, Documentation, and Prescriber Requirements

Prior Authorization

Product-specific non-covered/non-preferred criteria for Rituxan

When rituximab is prescribed as Rituxan, the plan requires that Non-Covered/Non-Preferred Product Criteria are met, including documented trials of listed biosimilars and a prescriber justification that the patient cannot continue the alternatives due to formulation differences in inactive ingredients (employer and IFP plans have specific trial lists).

Affected HCPCS codes: J9312, Q5115, Q5119, Q5123
Employer plans require trials of Riabni and Ruxience and documentation that alternatives cannot be used due to inactive ingredient differences
Individual & Family Plans require trials of Riabni, Ruxience, and Truxima and documentation that alternatives cannot be used due to inactive ingredient differences

Documentation Required

Documentation requirements

Submit required documentation where noted in the criteria; acceptable documentation includes chart notes, laboratory tests, claims records, and other information to support prior therapy failures, diagnostic confirmation (e.g., positive AQP4 for NMOSD), or response to prior rituximab.

Numeric and Timing Thresholds to Observe

Key clinical thresholds

ANCA-associated vasculitis (maintenance) minimum interval>= 16 weeks

Rheumatoid arthritis minimum interval between courses>= 16 weeks

ITP / SLE / MS minimum interval between courses (where specified)>= 6 months (ITP; SLE; MS) where noted

Membranous nephropathy proteinuria threshold> 3.5 g/day after 6 months conservative therapy or >1 g/day in recurrent transplant

Clinical and Product Background

Rituximab products are CD20-directed cytolytic antibodies administered by intravenous infusion. Intravenous rituximab products addressed in this policy include Rituxan and the biosimilars Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs).

These intravenous rituximab products have multiple FDA‑approved oncology indications and several non‑oncology indications (examples include antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, pemphigus vulgaris, and rheumatoid arthritis). When covered for non‑oncology uses, dosing regimens and specialist prescriber requirements vary by indication and are detailed in the medical necessity criteria and dosing sections of the policy.

Riabni, Ruxience, and Truxima are approved as biosimilars to Rituxan, meaning they have no clinically meaningful differences in safety and effectiveness compared with the reference product; however, at the time of this policy the biosimilars have demonstrated biosimilarity but are not approved as interchangeable with Rituxan.

Defined Terms

Documentation requiredChart notes, laboratory tests, claims records, and/or other information to support criteria; required where noted.

Course (of therapy)A treatment regimen as defined per indication (for example, two 1000 mg doses separated by 2 weeks for certain indications).

Neuromyelitis Optica Spectrum Disorder (NMOSD)An autoimmune central nervous system disorder often associated with aquaporin-4 autoantibodies; policy requires a positive AQP4 serum test for diagnostic confirmation for coverage.

Material Policy Changes

2025-08-15revisedLatest

Updated NMOSD diagnostic requirement: the NMOSD criterion was revised from a general documented diagnosis to requiring confirmation by a positive blood serum test for anti‑aquaporin‑4 antibody (documentation required).

2025-07-01revised

Preferencing Product Table changed: removed the prior-start condition 'Individual has previously started on or is currently receiving Rituxan (rituximab)' so operational systems should no longer require this prior-start documentation for preferencing decisions.

2025-08-15

Policy Summary

PayerCigna

PolicyRituximab products for non-oncology indications

Policy CodePolicy IP0319

Change TypeDocumentation and preferencing updates

Effective DateAug 15, 2025

Next Review Date

Key ActionWhen requesting coverage for NMOSD, submit documentation showing a positive anti-aquaporin-4 (AQP4) serum test and follow product-specific non-preferred criteria when Rituxan is prescribed.

SourceLink

On This Page

Documentation may include chart notes, labs, claims records, and other supporting information
Documentation required examples: positive anti-aquaporin-4 serum test for NMOSD, prior therapy failures, and evidence of response to prior rituximab

Prior Authorization

Specialty prescriber requirement

Ensure the medication is prescribed by or in consultation with the specialty appropriate for the indication (examples include rheumatology, nephrology, neurology, dermatology, hematology, or oncology) as specified in the criteria.

Rheumatologist — ANCA-associated vasculitis, rheumatoid arthritis, SLE, membranous nephropathy (with nephrology), MG
Nephrologist — ANCA-associated vasculitis, membranous nephropathy, SLE, pediatric nephrotic syndrome
Neurologist — NMOSD, MS, immunotherapy-related toxicities
Dermatologist — pemphigus vulgaris, autoimmune blistering diseases
Hematologist/Oncologist — ITP, TTP, GVHD, transplant-related uses

Prior Authorization

Treatment sequencing and concurrent therapy constraints

Follow required sequencing: document failure, contraindication, or intolerance to specified prior therapies before approval when noted, and do not use rituximab concurrently with another biologic or targeted synthetic DMARD as specified in the criteria.

Rheumatoid arthritis: trial of one conventional synthetic DMARD for ≥3 months unless exception; no concurrent biologic or targeted synthetic DMARD
MS and other indications: documentation of prior failure/intolerance to at least one alternative and at least 6 months between courses where specified
If criteria require, show documented failure/contraindication/intolerance to conventional systemic or immunosuppressive agents before approval

Denial Risk

Experimental/Unproven exclusions

Requests for rituximab for indications designated as experimental, investigational, or unproven — including specified concurrent use with Enspryng (satralizumab), Soliris (eculizumab), Ultomiris (ravulizumab), Uplizna (inebilizumab), and use of Rituxan Hycela for any non-oncology indication — are subject to denial.

Concomitant use with Enspryng, Soliris, Ultomiris, or Uplizna is considered unproven and not covered
Rituxan Hycela (rituximab and hyaluronidase human) is not covered for any non-oncology indication

Documentation Required

NMOSD diagnostic confirmation required

For NMOSD requests, include documentation showing the diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 (AQP4) antibody; this documentation is required in the prior authorization submission.

Positive anti-aquaporin-4 (AQP4) antibody blood serum test must be submitted with the PA

Documentation Required

Remove prior-start documentation for Rituxan (rituximab)

Do not include evidence that the individual previously started on or is currently receiving Rituxan when submitting prior authorization/product preferencing requests; the prior-start condition has been removed from the preferencing table and submissions should be updated accordingly.

Operational systems and PA submissions should not require documentation of prior or current Rituxan use for preferencing decisions

Added documentation instructions for NMOSD prior authorization specifying that diagnosis must be confirmed by a positive anti‑aquaporin‑4 (AQP4) blood serum test (documentation required).